Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells

DNA Repair

Volumn 6, Issue 8, 2007, Pages 1187-1196

  Schambach, Axel ^a   Baum, Christopher ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Lentiviral vector; Retroviral vector

Indexed keywords

6 O BENZYLGUANINE; ALKYLATING AGENT; CARMUSTINE; FLUOROURACIL; LENTIVIRUS VECTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETROVIRUS VECTOR; TEMOZOLOMIDE;

ARTICLE; CHIMERA; DNA ALKYLATION; DNA REPAIR; ENHANCER REGION; EPIGENETICS; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; HEMATOPOIETIC CELL; HUMAN; INTERNAL RIBOSOME ENTRY SITE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; RNA TRANSLATION;

AMINO ACID SUBSTITUTION; ANIMALS; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RECOMBINANT PROTEINS; RETROVIRIDAE; TUMOR SUPPRESSOR PROTEINS;

EID: 34447331660     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2007.03.017     Document Type: Article

References (122)

1. Neff T., Beard B.C., and Kiem H.P. Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107 5 (2006) 1751-1760
2. Milsom M.D., and Fairbairn L.J. Protection and selection for gene therapy in the hematopoietic system. J. Gene Med. 6 2 (2004) 133-146
3. Sorrentino B.P. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer 2 6 (2002) 431-441
4. Huang X., et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 107 2 (2006) 483-491
5. Thomas C.E., Ehrhardt A., and Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4 5 (2003) 346-358
6. Worsham D.N., et al. In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol. Ther. 14 4 (2006) 514-524
7. Kustikova O.S., et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102 (2003) 3934-3937
8. Zielske S.P., and Gerson S.L. Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: lack of copy number selection by drug treatment. Mol. Ther. 9 6 (2004) 923-931
9. Persons D.A., et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102 2 (2003) 506-513
10. Schambach A., et al. Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther. 13 (2006) 1037-1047
11. Davis B.M., Humeau L., and Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 9 2 (2004) 160-172
12. Richard E., et al. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection. Gene Ther. 11 22 (2004) 1638-1647
13. Aiuti A., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 5577 (2002) 2410-2413
14. Ott M.G., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12 4 (2006) 401-409
15. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4 4 (2004) 296-307
16. Williams D.A., et al. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J. Exp. Med. 166 1 (1987) 210-218
17. Pollok K.E., et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum. Gene Ther. 14 18 (2003) 1703-1714
18. Yamaguchi K., et al. In vivo selection of transduced hematopoietic stem cells and little evidence of their conversion into hepatocytes in vivo. J. Hepatol. (2006)
19. Cornetta K., et al. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase. Cancer Gene. Ther. 13 (2006) 886-895
20. Fontes A.M., et al. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells. Mol. Cancer Ther. 5 1 (2006) 121-128
21. Schambach A., et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Ther. 13 2 (2006) 391-400
22. Cai S., et al. In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells. Mol. Ther. 13 5 (2006) 1016-1026
23. Woolford L.B., et al. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J. Gene Med. 8 1 (2006) 29-34
24. Neff T., et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105 3 (2005) 997-1002
25. Milsom M.D., et al. Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4. Mol. Ther. 10 5 (2004) 862-873
26. Choi U., et al. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker. Exp. Hematol. 32 8 (2004) 709-719
27. Neff T., et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest. 112 10 (2003) 1581-1588
28. Davis B.M., et al. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients. J. Hematother. Stem Cell Res. 12 4 (2003) 375-387
29. Davis B.M., et al. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 57 22 (1997) 5093-5099
30. Bowman J.E., et al. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Mol. Ther. 8 1 (2003) 42-50
31. Wang J., et al. Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk. Res. 26 3 (2002) 281-288
32. Lee K., et al. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU. J. Hematother. Stem Cell Res. 10 5 (2001) 691-701
33. Jansen M., et al. Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones. Eur. J. Haematol. 67 1 (2001) 2-13
34. Sawai N., et al. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3 1 (2001) 78-87
35. Maze R., et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl. Acad. Sci. U.S.A. 93 1 (1996) 206-210
36. Chinnasamy D., et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol. J. 3 (2006) 14
37. Zielske S.P., et al. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J. Clin. Invest. 112 10 (2003) 1561-1570
38. Richard E., et al. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J. Gene Med. 5 9 (2003) 737-747
39. Longhurst S.J., et al. Recombinant adeno-associated virus-mediated expression of O6-alkylguanine-DNA-alkyltransferase protects human epithelial and hematopoietic cells against chloroethylating agent toxicity. Hum. Gene Ther. 10 2 (1999) 301-310
40. Davis B.M., et al. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum. Gene Ther. 10 17 (1999) 2769-2778
41. Ragg S., et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60 18 (2000) 5187-5195
42. Trobridge G., Beard B.C., and Kiem H.P. Hematopoietic stem cell transduction and amplification in large animal models. Hum. Gene Ther. 16 12 (2005) 1355-1366
43. Joyner A., et al. Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature 305 5934 (1983) 556-558
44. Williams D.A., et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310 (1984) 476-480
45. Kohn D.B. The current status of gene therapy using hematopoietic stem cells. Curr. Opin. Pediatr. 7 1 (1995) 56-63
46. Dunbar C.E. Gene therapy for hematologic disease: don't throw the baby out with the bathwater!. Semin. Hematol. 41 4 (2004) 1-2
47. Klein C., and Baum C. Gene therapy for inherited disorders of haematopoietic cells. Hematol. J. 5 2 (2004) 103-111
48. Kiem H.P., et al. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol. Ther. 9 3 (2004) 389-395
49. Horn P.A., et al. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 100 12 (2002) 3960-3967
50. Abonour R., et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat. Med. 6 6 (2000) 652-658
51. Santoni de Sio F.R., et al. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107 11 (2006) 4257-4265
52. Ailles L.E., and Naldini L. HIV-1-derived lentiviral vectors. Curr. Top. Microbiol. Immunol. 261 (2002) 31-52
53. Goff S.P. Retrovirus restriction factors. Mol. Cell 16 6 (2004) 849-859
54. Hanawa H., et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103 11 (2004) 4062-4069
55. Negre D., and Cosset F.L. Vectors derived from simian immunodeficiency virus (SIV). Biochimie 84 11 (2002) 1161-1171
56. Bartosch B., and Cosset F.L. Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr. Gene Ther. 4 4 (2004) 427-443
57. Woods N.B., et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101 4 (2003) 1284-1289
58. Mostoslavsky G., et al. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol. Ther. 11 6 (2005) 932-940
59. Kurre P., Anandakumar P., and Kiem H.P. Rapid 1-h transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells. Gene Ther. (2005)
60. Larochelle A., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107 9 (2006) 3772-3778
61. Sandrin V., et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100 3 (2002) 823-832
62. Budak-Alpdogan T., et al. Functional assessment of the engraftment potential of gammaretrovirus-modified CD34(+) cells, using a short serum-free transduction protocol. Hum. Gene Ther. 17 7 (2006) 780-794
63. Hacein-Bey-Abina S., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346 16 (2002) 1185-1193
64. Gaspar H.B., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 9452 (2004) 2181-2187
65. Wahlers A., et al. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Ther. 8 6 (2001) 477-486
66. Li Z., et al. Murine leukemia induced by retroviral gene marking. Science 296 5567 (2002) 497
67. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 5644 (2003) 415-419
68. Modlich U., et al. Leukemias following retroviral transfer of multidrug resistance 1 are driven by combinatorial insertional mutagenesis. Blood 105 (2005) 4235-4246
69. Seggewiss R., et al. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood 107 (2006) 3865-3867
70. Baum C., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101 6 (2003) 2099-2114
71. Baum C., et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. J. Virol. 69 (1995) 7541-7547
72. Challita P.M., et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69 (1995) 748-755
73. Logan A.C., Lutzko C., and Kohn D.B. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr. Opin. Biotechnol. 13 5 (2002) 429-436
74. Ramezani A., Hawley T.S., and Hawley R.G. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol. Ther. 2 (2000) 458-469
75. Ramezani A., Hawley T.S., and Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 101 (2003) 4717-4724
76. Cheng L., et al. Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. Blood 92 1 (1998) 83-92
77. Montini E., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24 6 (2006) 687-696
78. Modlich U., et al. Novel cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108 (2006) 2545-2553
79. Yu S.F., et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 3194-3198
80. Dull T., et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 11 (1998) 8463-8471
81. Schambach A., et al. Overcoming promoter interference in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther. 13 (2006) 1524-1533
82. Schucht R., et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp mediated site-specific integration of retroviral vectors. Mol. Ther. 14 2 (2006) 285-292
83. Ikeda Y., et al. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21 5 (2003) 569-572
84. Cockrell A.S., et al. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 14 2 (2006) 276-284
85. Dupuy A.J., et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436 7048 (2005) 221-226
86. Wu X., et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 5626 (2003) 1749-1751
87. Themis M., et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12 4 (2005) 763-771
88. Woods N.B., et al. Gene therapy: therapeutic gene causing lymphoma. Nature 440 7088 (2006) 1123
89. Emery D.W., et al. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. U.S.A. 97 16 (2000) 9150-9155
90. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 16 11 (2005) 1241-1246
91. Nienhuis A.W., Dunbar C.E., and Sorrentino B.P. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13 6 (2006) 1031-1049
92. Shou Y., et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U.S.A. 103 31 (2006) 11730-11735
93. Mizushima S., and Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res. 18 17 (1990) 5322
94. Woods N.B., et al. Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood 96 12 (2000) 3725-3733
95. Salmon P., et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96 10 (2000) 3392-3398
96. Chinnasamy D., et al. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Hum. Gene Ther. 15 8 (2004) 758-769
97. Krall W.J., et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 3 1 (1996) 37-48
98. Zufferey R., et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73 (1999) 2886-2892
99. Schambach A., et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2 5 (2000) 435-445
100. Kim S.H., et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol. 72 (1998) 994-1004
101. Hildinger M., et al. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J. Virol. 73 5 (1999) 4083-4089
102. Schambach A., et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 13 7 (2006) 641-645
103. Hope T. Improving the post-transcriptional aspects of lentiviral vectors. Curr. Top. Microbiol. Immunol. 261 (2002) 179-189
104. Kraunus J., et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 11 (2004) 1568-1578
105. Lee J.T., et al. Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector. Gene Ther. 11 1 (2004) 94-99
106. Ismail S.I., et al. Split-intron retroviral vectors: enhanced expression with improved safety. J. Virol. 74 5 (2000) 2365-2371
107. Li K.J., and Garoff H. Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3650-3654
108. Chang D.D., and Sharp P.A. Regulation by HIV Rev depends upon recognition of splice sites. Cell 59 5 (1989) 789-795
109. Zaiss A.K., Son S., and Chang L.J. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J. Virol. 76 14 (2002) 7209-7219
110. Kingsman S.M., Mitrophanous K., and Olsen J.C. Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther. 12 1 (2005) 3-4
111. Amendola M., et al. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23 1 (2005) 108-116
112. Greenberger J.S., et al. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines. Proc. Natl. Acad. Sci. U.S.A. 80 10 (1983) 2931-2935
113. Metzger D., et al. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc. Natl. Acad. Sci. U.S.A. 92 15 (1995) 6991-6995
114. Barde I., et al. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Mol. Ther. 13 2 (2006) 82-90 3
115. Kafri T., et al. Lentiviral vectors: regulated gene expression. Mol. Ther. 1 6 (2000) 516-521
116. Vigna E., et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol. Ther. 5 3 (2002) 252-261
117. Rund D., et al. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum. Gene Ther. 9 5 (1998) 649-657
118. Yanez-Munoz R.J., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12 3 (2006) 348-353
119. Nightingale S.J., et al. Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 13 6 (2006) 1121-1132
120. Bode J., and Maass K. Chromatin domain surrounding the human interferon-beta gene as defined by scaffold-attached regions. Biochemistry 27 13 (1988) 4706-4711
121. Baiker A., et al. Mitotic stability of S/MAR containing episomal vectors is provided by nuclear matrix association. Nat. Cell Biol. 2 (2000) 182-184
122. Jenke A.W., et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11322-11327